Abrams Capital Management’s Teva Pharmaceuticals TEVA Stock Holding History

Abrams Capital Management’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-5,996,836	Closed	-$62.6M	–	14
2023 Q4	$62.6M	Sell	5,996,836 -1,969,597	-25%	-$18.4M	1.95%	11
2023 Q3	$81.3M	Hold	7,966,433	–	–	2.68%	11
2023 Q2	$60M	Hold	7,966,433	–	–	1.73%	13
2023 Q1	$70.5M	Sell	7,966,433 -7,966,432	-50%	-$78.8M	2.23%	12
2022 Q4	$145M	Sell	15,932,865 -7,966,431	-33%	-$69.5M	5.18%	10
2022 Q3	$193M	Sell	23,899,296 -147,060	-0.6%	-$1.3M	5.56%	10
2022 Q2	$181M	Hold	24,046,356	–	–	4.86%	11
2022 Q1	$226M	Hold	24,046,356	–	–	5.27%	12
2021 Q4	$193M	Hold	24,046,356	–	–	4.23%	12
2021 Q3	$234M	Hold	24,046,356	–	–	5.11%	9
2021 Q2	$238M	Hold	24,046,356	–	–	5.29%	9
2021 Q1	$277M	Hold	24,046,356	–	–	6.25%	7
2020 Q4	$232M	Hold	24,046,356	–	–	6.54%	8
2020 Q3	$217M	Hold	24,046,356	–	–	6.85%	6
2020 Q2	$296M	Hold	24,046,356	–	–	9.58%	2
2020 Q1	$216M	Hold	24,046,356	–	–	8.5%	3
2019 Q4	$236M	Hold	24,046,356	–	–	7.32%	5
2019 Q3	$165M	Buy	24,046,356 +6,000,000	+33%	+$46M	4.63%	12
2019 Q2	$167M	Hold	18,046,356	–	–	4.52%	10
2019 Q1	$283M	Sell	18,046,356 -476,016	-3%	-$8.39M	7.95%	5
2018 Q4	$286M	Sell	18,522,372 -1,000,000	-5%	-$20.5M	11.8%	3
2018 Q3	$421M	Sell	19,522,372 -220,751	-1%	-$5.12M	11.12%	1
2018 Q2	$480M	Hold	19,743,123	–	–	13.36%	1
2018 Q1	$337M	Hold	19,743,123	–	–	10.58%	2
2017 Q4	$374M	Sell	19,743,123 -1,880,763	-9%	-$28.3M	12.6%	2
2017 Q3	$381M	Buy	+21,623,886	New	+$487M	14.85%	2
2013 Q3	–	Sell	-2,561,269	Closed	-$100M	–	13
2013 Q2	$100M	Buy	+2,561,269	New	+$99.7M	5.81%	6

Other funds holding TEVA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

IAM

Ion Asset Management Herzliya, Israel $911M AUM 24.97% 1-Year Est. Return

Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return

MIFH

Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return

Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return

MMH

Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return

SPC

Slate Path Capital New York $6.73B AUM 95.97% 1-Year Est. Return

LIM

Lingotto Investment Management London, United Kingdom $5.06B AUM 91.14% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Abrams Capital Management's TEVA Position: Q1 2024 in Review

Abrams Capital Management sold out of Teva Pharmaceuticals (TEVA) in Q1 2024, closing a stake of 5,996,836 shares — an estimated $62.6M sold.

Abrams Capital Management first reported a position in TEVA in Q2 2013 and held it in 27 quarters. The position peaked at $480M in Q2 2018. 481 funds tracked by Wall St. Rank hold TEVA as of Q1 2024.

Abrams Capital Management reported no remaining Teva Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
Abrams Capital Management sold 5,996,836 Teva Pharmaceuticals shares in Q1 2024, an estimated $62.6M.
Abrams Capital Management first reported a position in Teva Pharmaceuticals in Q2 2013 and held it in 27 quarters.
Abrams Capital Management's Teva Pharmaceuticals position peaked at $480M in Q2 2018.
481 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q1 2024.

Based on Abrams Capital Management's 13F filing for Q1 2024, filed 14 May 2024.